Yes. We keep the group small and the environment deliberately low-pressure. Whether you are an experienced angel investor, a physician curious about early-stage investing, or a sophisticated investor who sees the opportunity in ophthalmology, Observer Membership is the ideal starting point. Start there and see where it takes you.

Membership is limited to individuals who qualify as accredited investors under applicable securities regulations. We welcome ophthalmologists, scientists, industry leaders, and sophisticated investors who share an interest in early-stage ophthalmic innovation. You do not need to be a physician or healthcare professional to participate meaningfully.

Observer Membership carries no annual fee and no-obligation. It is designed for investors who want to experience EyeSci Angels before committing capital. Observer Members attend selected company presentations, access selected diligence materials and educational resources, observe group discussions, and attend social gatherings at major national ophthalmology meetings. There is no fee to join and no pressure to upgrade. Observer Members may convert to Investor Membership at any time.

No. EyeSci Angels operates on a deal-by-deal basis. There are no capital commitments, no mandates, and no pressure. You participate in what interests you and pass on what does not, every time, on your own terms.

We cover ophthalmology and vision science exclusively — biotech, medical devices, diagnostics, pharmaceuticals, and enabling platforms across the full spectrum of eye care. We focus on seed and pre-Series A companies where informed early capital can make a meaningful difference.

Yes. Our principals invest personally in every opportunity we bring to the group. This is a deliberate choice that keeps incentives fully aligned with members. Carried interest means we participate in returns only when members realize them.

We evaluate each opportunity across five core dimensions:

• Clinical coherence - whether the clinical problem is meaningful and the proposed solution fits realistically within clinical practice

• Scientific and technical rationale - whether the underlying science or engineering is credible and supported by available data

• Regulatory pathway - whether the company has a plausible and well-considered route to regulatory approval

• Capital efficiency - whether the financing is structured to advance the company to a clear development milestone

• Founder and team - whether the team demonstrates the clarity, transparency, and openness to rigorous engagement required to navigate early-stage development

The strongest opportunities demonstrate coherence across all five.